Fludarabine is commonly used in combination with busulfan as part of conditioning regimens before allogeneic stem cell transplantation. So far, no data are available on busulfan-fludarabine drug interactions in transplant recipients. The pharmacokinetic (PK) properties of F-ara-A (9-b-D-arabinosyl-2-fluoradenine) before and after application of busulfan were prospectively investigated in 16 patients with hematological malignancies. The conditioning regimen consisted of intravenous fludarabine 30 mg/m 2 over 30 min from day À6 to day À3, and oral busulfan given at 1 mg/kg every 6 h from day À5 to day À2. PK parameters of F-ara-A, derived from plasma and urine on day À6, À5, À4 and À3, were determined using high-performance liquid chromatography (HPLC). AUC, C max , t 1/2 , Cl total and V SS were 21.9 lMh, 3.5 lM, 13.0 h, 4.3 l/h/m 2 , 60.0 l/m 2 on day À6 and 22.4 lMh, 3.5 lM, 14.0 h, 4.7 l/h/m 2 , 69.0 l/m 2 on day À5 to (À2), respectively. Cl renal and the urine-recovery were 4.8 l/h, 43.7% of the fludarabine dose on day À6 and 3.9 l/h, 44.2% of the fludarabine dose on day À5 to (À2), respectively. There were no changes in PK parameters of fludarabine given before and after intake of busulfan. This implies that a clinically relevant busulfan-fludarabine drug interaction is unlikely.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for certain patients with malignant or non-malignant disorders. As a result of the considerable toxicity of the conventional conditioning regime and the high risk of transplant-related (non-relapse) mortality, reduced-intensity conditioning (RIC) protocols preserving the graft-versus-leukemia (GVL) effect and allowing for stable engraftment have been developed. In many RICs cyclophosphamide has been replaced by fludarabine.
Beneath the myelosuppressive effect of fludarabine, central nervous system (CNS) toxicity (including blindness, coma and death) is a dose-limiting side effect. CNS toxicity mainly occurs in patients receiving high doses of the drug (up to 36% at 480 mg/m 2 over 5-7 days). In doses o125 mg/m 2 per course CNS adverse events are rarely observed (o1%). 1 The standard dose is 20-30 mg/m 2 /d given over 30 min for 4-5 days.
Fludarabine (9-b-D-arabinosyl-2-fluoradenine-5 0 -monophosphate), a purine analog antimetabolite, is a prodrug that is immediately dephosphorylated in plasma to the free nucleoside F-ara-A (9-b-D-arabinosyl-2-fluoradenine). F-ara-A is taken into cells by nucleoside transporters and accumulates mainly as the 5 0 triphosphate, F-ara-ATP. The rate-limiting step in the formation of the intracellular triphosphate is the conversion of F-ara-A to its monophosphate (F-ara-AMP) by deoxycytidine-kinase. F-ara-ATP represents the main cytotoxic agent by inhibiting DNA and RNA synthesis, developing antileukemic and immunosuppressive properties. 2, 3 Despite interindividual differences in intracellular F-ara-ATP formation, in some studies proportionality between the dose of the drug and the cellular concentration of the active metabolite has been proposed. 4 Fludarabine is administered alone as well as in combination with other chemotherapeutic drugs, including cyclophosphamide, busulfan, rituximab and ara-C (cytosinarabinoside). The rational approach for combinationtherapy is mostly based on agonism/synergism on the cellular level leading to enhanced cytotoxic effects. For example, fludarabine is used to modulate the cellular metabolism of ara-C. Given before ara-C an increase in inducing apoptosis can be observed, possibly by ameliorating the incorporation of ara-CTP (the triphosphate of ara-C) into DNA. [4] [5] [6] Unfortunately not only additive therapeutic action is seen in combination therapy but also often a rise in adverse events. In part, the increase in side effects can be reduced to changes in pharmacokinetic properties.
As a result of the short half-life of the prodrug in plasma, fludarabine is not accessible for pharmacokinetic analysis. Therefore, measurement of F-ara-A, the dephosphorylated metabolite, is widely used for pharmacokinetic studies. The pharmacokinetic properties of fludarabine given alone (oral, subcutaneous and intravenous administration, bolus and continuous infusion) have been studied in several trials. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] As fludarabine is used in combination with busulfan as part of reduced intensity conditioning regimens for allogeneic stem cell transplantation mostly in older and intensively pretreated patients, we examined whether the application of busulfan before the fludarabine administration could lead to altered pharmacokinetic properties of F-ara-A due to changes in protein binding and hepatic impairment leading to an increased risk of adverse effects, for example CNS toxicities.
Materials and methods

Patients
A group of 16 patients between 33 and 66 years (median 51.6) of age were analyzed in this study: five (31.3%) with AML (according to FAB-classification), three (18.8%) with multiple myeloma, three (18.8%) with MDS (according to FAB-classification), two (12.5%) with CLL, one at a time (6.3%) with plasma cell leukemia, ALL or renal cell carcinoma. Table 1 provides baseline characteristics of the patients. All patients had adequate hepatic function (total bilirubin o1.5 normal for age, alanine aminotransferase less that three times normal for age, and albumin 420 g/l) and adequate renal function (serum creatinine o1.5 normal for age) at the beginning of the treatment. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consisted of intravenous fludarabine 30 mg/m 2 over 30 min from day À6 to day À3, and oral busulfan given at 1 mg/kg every 6 h from day À5 to day À2. The patient underwent allogeneic hematopoietic stem cell transplantation on day 0.
Blood and urine sample collection Blood samples from 12 patients were taken on day À6 (before busulfan application) and day À4 (post-busulfan application) at various time points (predose, 0, 1, 2, 3, 5, 7, 9, 12 h after fludarabine infusion). Blood samples from two patients were taken on day À6 and day À3, from one patient on day À6 and day À5 and from another patient only on day À4 at the same time points mentioned above.
A 24h-urine collection on day À6 and day À4 has been carried out in 11 patients, additionally on day À5 in seven patients and on day À3 in one patient. No urine data are available for four patients.
HPLC and sample preparation Plasma and urine concentrations for F-ara-A were determined by a previously reported precolumn sample derivatisation and a high-performance liquid chromatography (HPLC) measurement with fluorescence-detection. 12 Briefly, heparinized blood samples (5-10 ml) were spiked with 0.1 mmol/l erythro-9-(2-hydroxy-3-nonyl) adenine. After centrifugation for 20 min at 500 g and 41C, the supernatant was removed and afterwards F-ara-A was obtained by solid-phase extraction (SEP-PAK C 18 ). F-ara-A was eluted in alkaline methanol. Methanol was evaporated completely in a SpeedVac. Citrate buffer and chloroacetaldehyde were added to the dry sample, following incubation in a 501C water bath for 24 h. Urine samples were spiked with 0.1 mmol/l erythro-9-(2-hydroxy-3-nonyl)adenine. Subsequently the sample was centrifuged and the supernatant diluted with water. Citrate buffer and chloroacetaldehyde were added, followed by an incubation in a 501C water bath for 24 h. Before HPLC-measurement, the samples were diluted again with citrate buffer. The HPLC-system was composed of a WATERS 700 satellite WISP, a WATERS 600E system control, a JASCO 820-FP fluorescence detector and a data acquisition box (NUCLE-AR INTERFACE). As the stationary phase, a C 18 column (NUCLEOSIL, 250 Â 4 mm, 3 mM particle size) with a 10 mm precolumn filter was used. The mobile phase consisted of 2% methanol and 5% N, N-dimethylformamide in water, used under isocratic conditions (flow rate 1 ml/min). Excitation wavelength was 296 nm, emission wavelength 410 nm.
Pharmacokinetic calculations
Data from all subjects were included in the pharmacokinetic analysis. The following PK parameters were calculated: C max indicates maximum calculated plasma concentration, t 1/2 apparent terminal disposition half-life, AUC area under the concentration-time curve, V SS volume of distribution at steady-state, Cl total total body drug clearance and Cl renal renal drug clearance. Pharmacokinetic parameters were determined utilizing the TOPFIT computer program providing an optimized adaption of variation coefficients between the observed and calculated respective data. 17 As weighting function for the measured data 1/y 2 was used. An optimal regression coefficient 40.98 was found in all patients by using a linear two compartment model assuming a classical first order absorption constant described by the equation:
with C p is the plasma concentration at a specific time point, t is time, A is the plasma concentration at time point 0 of the distribution-curve, B is the plasma concentration at time point 0 of the elimination-curve, a and b are elimination rate constants.
Statistical analysis
To compare PK parameters of F-ara-A from day À6 (before busulfan application) with day À5 to (À3) (postbusulfan application) all PK data were calculated and described for the first day of application so a possible accumulation of F-ara-A did not influence the results.
The following pharmacokinetic parameters were used to assess the interaction between busulfan and F-ara-A: t 1/2 , Table 2 PK parameters of F-ara-A before (day À6) and after (day À5 to (À3)) busulfan application (calculated as first day of application) 
Results
Both measured concentrations and mean plasma concentration-time profile of F-ara-A for the 16 patients are depicted in Figure 1 . Cumulative urine elimination of Fara-A as a function of time is shown in Figure 2 . The time points of fludarabine and busulfan application are marked. These data were used to determine the PK parameters for every single patient, given in Table 2 . PK parameters were calculated independently for every single day, for comparison reason as first day of application.
The average t 1/2 of F-ara-A before busulfan application was 8. .51716.45%, respectively. There were no statistically significant changes in pharmacokinetic properties of F-ara-A before (day À6) and after (day À5 to (À3)) busulfan application. Cl renal and urine-recovery were apparently reduced in the postbusulfan group, but no stastically significant level was reached. Median, s.d., VC and P-value of the PK parameters for both groups are listed in Table 3 .
Discussion
The pharmacokinetic profile of F-ara-A in our study was comparable to that described by other groups in patients receiving conventional chemotherapy. [11] [12] [13] [14] [15] This is of special interest, since patients undergoing reduced-intensity conditioning therapy before allogeneic HSCT represent a heavily pretreated population in which impaired organ function can be assumed.
Recent in vitro studies suggest that so far unknown proapoptotic effects of fludarabine on endothelial cells could be related to specific organ toxicities observed after allogeneic HSCT. 18 In addition, the relatively frequent occurrence of thrombotic microangiopathy after reducedintensity conditioning could be related to the specific mode of action of fludarabine. 19 Our data suggest that these specific toxicities are probably not due to an increased exposition of transplant recipients towards F-Ara-A. In our study, C max and AUC on day À6 (before busulfan application) were 4.2872.21 mM (VC 51.57%) and 21.557 6.84 mMh (VC 31.73%), respectively. As mentioned above, this is comparable to several pharmacokinetic studies in which a standard dose of fludarabine (25-30 mg/m 2 over 30 min) resulted in a C max and AUC of about 3-4 mMol and 15-20 mMh, respectively. The linear increase with the dose in AUC and C max dose-independent behavior for t 1/2 , V SS and Cl total have been described previously. 15 In most investigations sampling continued for 24-30 h, resulting in a terminal half-life of 8-10 h, compared to 8.974.8 h in this setting. [12] [13] [14] [15] When additional sampling points up to 72 h were taken into account, t 1/2 was calculated at 30 h. The clinical impact of this observation is not clear, because no accumulation of the drug (increase in AUC or C max ) has been seen when fludarabine is given every 24 h in patients with adequate renal function. 12 The volume of distribution at steady-state (V SS ) on day À6 (before busulfan application) was 53.4731.0 l, comparable to 35-60 l in other pharmacokinetic studies, indicating extra-plasmatic accumulation.
11,14,15 F-ara-A was mainly eleminated by renal excretion, recognizable by high renal clearance and urine-recovery. Cl total and Cl renal were Table 3 PK parameters before and after busulfan application (calculated as first day of application) 12, 14 In patients with lupus-nephritis (without severe impairment of renal function, creatinine o220 mMol/l) Cl total , AUC, V SS and t 1/2 lay in the expected range, but Cl renal and urine-recovery were reduced to 3.7 l/h and 26.1%, respectively.
14 Thus, according to most of the manufacturers, a dose-reduction up to 50% is recommended, if creatinine-clearance is between 30 and 70 ml/min.
After busulfan application, there were no statistically significant changes in PK parameters of F-ara-A (Table 3) . Still, a tendency towards a reduction in Cl renal and urine-recovery after busulfan application was detectable, without an increase in AUC and C max of F-ara-A (Table 3 and Figure 3 ). Given a linear increase with the dose in AUC and C max , the lower range of the estimated AUC for 100 mg/m 2 /day was not reached by any patient, the lower range of the estimated C max for 100 mg/m 2 /day was reached by five patients (two in the before and three in the post-busulfan application group, always different patients).
Whether the reduction of renal excretion of F-ara-A is caused by the various co-medications (e.g. antimicrobial chemotherapy) or other treatment-specific circumstances remains uncertain. This phenomenon did not lead to altered levels of AUC and C max . As high levels of AUC and C max of F-ara-A have been linked to CNS toxicity, a rise in CNS toxicities (post-busulfan application) by F-ara-A triggered by increased AUC and C max seems to be unlikely. These observations confirm the safety of fludarabine administration as part of reduced intensity conditioning regimens. Except for patients with impaired renal function, F-ara-A plasma concentration measurement may not be necessary. In summary we found no evidence for a relevant drug interaction between fludarabine and busulfan.
